REDWOOD CITY, Calif. , Nov. 18, 2020 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the recent publication by

REDWOOD CITY, Calif. , Nov. 6, 2020 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management will be

Third quarter product sales of $1.3M, up significantly compared to $0.3M in the second quarter   The Zimmer Biomet collaboration, addition of DSUVIA® to the U.S. Department of Defense Joint Deployment Formulary and the U.S. Army contract highlight third quarter achievements and growth opportunities

REDWOOD CITY, Calif. , Oct. 29, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release third quarter financial results after market close on Thursday, November 5, 2020 .

REDWOOD CITY, Calif. , Sept. 29, 2020 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced it will host a virtual

DSUVIA contract award for up to $3.6 million from the U.S. Army   Contract award in addition to expected purchases for medical assemblages and sets, kits and outfits REDWOOD CITY, Calif. , Sept. 22, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty

DSUVIA now available to all branches of the military   Availability expanded beyond Milestone C approval for Army sets, kits and outfits REDWOOD CITY, Calif. , Sept. 14, 2020 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the

REDWOOD CITY, Calif. , Sept. 10, 2020   /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will be

REDWOOD CITY, Calif. , Aug. 24, 2020 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced an investigator-initiated

REDWOOD CITY, Calif. , Aug. 19, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of a study entitled

U.S. Army Milestone C approval and exclusive distribution agreement with Zimmer Biomet for dental surgery highlight second quarter and recent achievements REDWOOD CITY, Calif. , Aug. 10, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company

REDWOOD CITY, Calif. , Aug. 3, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Monday, August 10, 2020 . AcelRx management will host a live webcast and

AcelRx expands DSUVIA commercial opportunity with an established, leading partner to advance oral surgical care REDWOOD CITY, Calif. , July 23, 2020 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced an agreement to market DSUVIA®, a

Investment by two leading life science investors, Armistice Capital and Rock Springs Capital REDWOOD CITY, Calif. , July 23, 2020 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative

AcelRx to be paid a break-up fee of $1.8 million upon termination of the merger agreement by Tetraphase REDWOOD CITY, Calif. , June 3, 2020 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of

REDWOOD CITY, Calif. , June 1, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management will be

Under revised terms, AcelRx to acquire Tetraphase for $30.0 million in stock and cash, plus an additional $14.5 million in CVRs Continues to believe Tetraphase acquisition complements AcelRx's commercial strategy and will deliver long-term shareholder value Co-promotion agreement for XERAVA and

Expects to See Strong Volume of Orders from U.S. Military Following Milestone C Approval for DSUVIA Provides Updates on Tetraphase Transaction REDWOOD CITY, Calif. , May 11, 2020 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on

REDWOOD CITY, Calif. , May 4, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release first quarter financial results after market close on Monday, May 11, 2020 . AcelRx management will host a live webcast and

Milestone C decision clears the way for the military to begin procuring DSUVIA REDWOOD CITY, Calif. , April 30, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for

Exceeds 2019 metrics with 166 REMS-certified facilities and 148 formulary approvals through December 31, greater than the year-end goals of 125 for each Reiterates year-end 2020 REMS-certified facilities and formulary approval goals of 465 223 formulary approvals and 218 REMS-certified facilities

AcelRx to acquire Tetraphase in a stock for stock transaction Tetraphase shareholders to receive 14.6% of AcelRx fully diluted shares outstanding in the transaction Transaction broadens AcelRx's portfolio and enhances its commercial presence and strategy to become a leader in providing innovative

REDWOOD CITY, Calif. , March 11, 2020 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter and annual financial results before market open on Monday, March 16, 2020 .

DSUVIA procurement expected following completion of Milestone C meeting REDWOOD CITY, Calif. , March 10, 2020 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in

REDWOOD CITY, Calif. , March 6, 2020 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced an agreement with Brigham and

Exceeds 2019 metrics with 166 REMS-certified facilities and 148 formulary approvals through December 31, greater than the year-end goals of 125 for each Announces year-end 2020 REMS-certified facilities and formulary approvals goals of 465 $66.1 million of cash and short-term investments at

REDWOOD CITY, Calif. , Nov. 13, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced a publication analyzing pooled

Exceeded 125 REMS-certified facilities two months ahead of year-end goal 105 formulary approvals through October 31 $80.4 million of cash and short-term investments at September 30, 2019 REDWOOD CITY, Calif. , Nov. 6, 2019 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc.

REDWOOD CITY, Calif. , Nov. 5, 2019 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management will be

REDWOOD CITY, Calif. , Oct. 28, 2019 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release third quarter financial results after market close on Wednesday, November 6, 2019 .

REDWOOD CITY, Calif. , Oct. 16, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an upcoming presentation

REDWOOD CITY, Calif. , Aug. 15, 2019 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that Dr.

51 REMS-certified facilities and 43 formulary approvals since launch Entered second phase of commercial plan moving from 15 hospital account managers to 40 in July $91.5 million of cash and short-term investments at June 30, 2019 REDWOOD CITY, Calif. , Aug.

REDWOOD CITY, Calif. , Aug. 2, 2019 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Monday, August 5th, 2019 .

REDWOOD CITY, Calif. , July 1, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings,  today announced that the Company has been added as

REDWOOD CITY, Calif. , June 3, 2019 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the closing of a $25 million senior

REDWOOD CITY, Calif. , May 8, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its first quarter 2019

REDWOOD CITY, Calif. , April 25, 2019 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release first quarter financial results after market close on Wednesday, May 8th, 2019 .

REDWOOD CITY, Calif. , April 11, 2019 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an abstract about the safety of

REDWOOD CITY, Calif. , March 11, 2019 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management will be

- DSUVIA now available for use in certified medically supervised healthcare settings, with initial shipments to wholesalers completed in the second half of February 2019 - Executed contracts with Group Purchasing Organizations (GPOs) covering approximately 80% of commercial launch targets - Cash,

REDWOOD CITY, Calif. , Feb. 22, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter and annual financial results after market close on Thursday, March 7th, 2019 .

REDWOOD CITY, Calif. , Jan. 31, 2019 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced a presentation about DSUVIA™ and

- Over 800 patients from AcelRx studies supporting DSUVIA™ approval were included in the pooled safety analysis - Initial dosing of 30 mcg sufentanil sublingual tablet calculated as dose-equivalent to 5 mg of IV morphine REDWOOD CITY, Calif. , Jan. 7, 2019 /PRNewswire/ --  AcelRx Pharmaceuticals,

REDWOOD CITY, Calif. , Dec. 18, 2018 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced it has been selected for

Update on DSUVIA U.S. commercialization strategy and insights from key healthcare professionals REDWOOD CITY, Calif. , Nov. 29, 2018 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx),  a specialty pharmaceutical company focused on the development and commercialization of

REDWOOD CITY, Calif. , Nov. 14, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced an upcoming presentation at the

REDWOOD CITY, Calif. , Nov. 9, 2018 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) today announced the pricing of its previously announced underwritten public offering of 12,698,412 shares of its common stock, at a public offering price of $3.15 per share.

REDWOOD CITY, Calif. , Nov. 9, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. AcelRx expects to grant the underwriters a 30-day

REDWOOD CITY, Calif. , Nov. 7, 2018 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management will be

- FDA approved DSUVIA™ for use in adults in a certified medically supervised healthcare setting for the management of acute pain - September 30, 2018 cash, cash equivalents and short-term investments balance of $63.6 million - Combined R&D and G&A expenses declined 17% from YTD 2017 REDWOOD CITY,

- DSUVIA (sufentanil sublingual tablet 30 mcg) is indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings - First and only sufentanil sublingual tablet approved for acute pain in healthcare

REDWOOD CITY, Calif. , Oct. 19, 2018 /PRNewswire/ -- In response to opinions expressed following the U.S. Food and Drug Administration ( FDA ) Anesthetic and Analgesic Drug Products Advisory Committee meeting on October 12 , AcelRx Pharmaceuticals, Inc.

REDWOOD CITY, Calif. , Oct. 15, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in a medically supervised setting, today announced a poster presentation at

REDWOOD CITY, Calif. , Oct. 12, 2018 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, announced today that the Anesthetic and Analgesic Drug Products Advisory Committee

REDWOOD CITY, Calif. , Oct. 12, 2018 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx),  a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in a medically supervised setting, today announced that NASDAQ has halted

REDWOOD CITY, Calif. , Sept. 25, 2018 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management will be

DSUVIA Advisory Committee meeting date set for October 12, 2018 REDWOOD CITY, Calif. , Sept. 11, 2018 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings,

REDWOOD CITY, Calif. , Aug. 23, 2018 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that it will be featured as a

REDWOOD CITY, Calif. , Aug. 20, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that Dr.

REDWOOD CITY, Calif. , Aug. 8, 2018 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) (AcelRx), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced that the underwriters of its previously announced underwritten

- European Commission approved DZUVEO (sufentanil sublingual tablet, 30 mcg) for the management of acute moderate-to-severe pain in adults in medically monitored settings - June 30, 2018 cash and short-term investments balance of $50.1 million - Combined R&D and G&A expenses declined 27% from H1

REDWOOD CITY, Calif. , July 19, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Thursday, August 2nd, 2018 .

REDWOOD CITY, Calif. , July 12, 2018 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) today announced the pricing of its previously announced underwritten public offering of 7,272,727 shares of its common stock, at a public offering price of $2.75 per share.

REDWOOD CITY, Calif. , July 11, 2018 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) today announced that it has commenced an underwritten public offering of shares of its common stock. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of

AcelRx's DZUVEO receives EU approval for management of acute moderate to severe pain in medically monitored settings REDWOOD CITY, Calif. , June 27, 2018 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative

DSUVIA PDUFA date set for November 3, 2018 REDWOOD CITY, Calif. , May 24, 2018 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced the

REDWOOD CITY, Calif. , May 23, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced that all of AcelRx shares owned by Three Arch

REDWOOD CITY, Calif. , May 22, 2018 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that Vince Angotti , Chief

- DSUVIA™ (sufentanil sublingual tablet, 30 mcg) New Drug Application (NDA) resubmitted to U.S. Food and Drug Administration (FDA) - March 31, 2018 cash and short-term investments balance of $51.2 million - Combined R&D and G&A expenses declined 32% from Q1 2017, conserving cash for anticipated

REDWOOD CITY, Calif. , May 9, 2018 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced the resubmission of the New Drug Application (NDA)

REDWOOD CITY, Calif. , April 30, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of two studies

DZUVEO is AcelRx's second developed sublingual sufentanil-based product to receive positive CHMP opinion, with Zalviso® already approved Resubmission of New Drug Application for DSUVIA™ (known as DZUVEO in Europe) to the FDA in the U.S. is planned for Q2 2018 REDWOOD CITY, Calif.

REDWOOD CITY, Calif. , April 25, 2018 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release first quarter financial results after market close on Wednesday, May 9th, 2018 .

REDWOOD CITY, Calif. , April 18, 2018 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, announced the publication of an analysis of the

REDWOOD CITY, Calif. , April 16, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced the successful completion of the human factors

REDWOOD CITY, Calif. , April 11, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported the publication of a report

REDWOOD CITY, Calif. , March 27, 2018 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx" or the "Company"), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced the appointment of John Saia as General

- FDA Type A meeting in January 2018 provides path to DSUVIA™ NDA resubmission expected in Q2 2018 - $60.5 million of cash and short-term investments at December 31, 2017 - Q4 2017 combined G&A and R&D expenses declined 27% from Q4 2016 and 9% from Q3 2017 REDWOOD CITY, Calif.

REDWOOD CITY, Calif. , March 8, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced the receipt of the official January 2018 Type A

REDWOOD CITY, Calif. , March 5, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that that

REDWOOD CITY, Calif. , March 2, 2018 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter and yearly financial results after market close on Thursday, March 8th, 2018 .

REDWOOD CITY, Calif. , Feb. 16, 2018 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that Vincent

REDWOOD CITY, Calif. , Nov. 16, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, reported the publication of a manuscript

- $67.9 million of cash and cash equivalents at September 30, 2017 - Type A FDA meeting requested and Briefing Book submitted to FDA regarding DSUVIA complete response letter (CRL) REDWOOD CITY, Calif. , Nov. 9, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.

REDWOOD CITY, Calif. , Nov. 9, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, reported the publication of a manuscript

REDWOOD CITY, Calif. , Oct. 30, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company, today announced that it will release third quarter financial results after market close on Thursday, November 9th .

DSUVIA clinical trial results was one of the top eight abstracts featured as an oral presentation at an opioid pharmacotherapy symposium at ANESTHESIOLOGY® 2017 REDWOOD CITY, Calif. , Oct. 20, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc.  (Nasdaq: ACRX) (AcelRx), a specialty pharmaceutical,

REDWOOD CITY, Calif. , Oct. 12, 2017 /PRNewswire/--  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) (AcelRx), a specialty pharmaceutical company, today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration ( FDA ) regarding its New Drug Application

REDWOOD CITY, Calif. , Sept. 6, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that Vincent

- Study Objective Achieved with 2.2% of Patients Experiencing a Device Error - - AcelRx Remains on Track to Resubmit NDA by End of 2017 - REDWOOD CITY, Calif., Aug. 1, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and

REDWOOD CITY, Calif., Aug. 1, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today provided a business update

REDWOOD CITY, Calif., July 31, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that it will

REDWOOD CITY, Calif., July 19, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced the appointment of Raffi

REDWOOD CITY, Calif., June 1, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that ZALVISO

REDWOOD CITY, Calif., May 31, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Vincent J.

- NDA for DSUVIA (sufentanil sublingual tablet, 30 mcg) and MAA for ARX-04 under review at respective agencies - REDWOOD CITY, Calif., May 8, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development

REDWOOD CITY, Calif. , April 26, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that it will

REDWOOD CITY, Calif. , April 13, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that Grunenthal, the

REDWOOD CITY, Calif. , April 6, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that efficacy and integrated

CHMP Opinion Expected First Half 2018 REDWOOD CITY, Calif. , March 28, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain,

REDWOOD CITY, Calif. , March 17, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that Senior

REDWOOD CITY, Calif. , March 16, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, will present data from the DSUVIA™

- DSUVIA NDA Accepted and PDUFA Date Set for October 12, 2017 - REDWOOD CITY, Calif. , March 2, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment

REDWOOD CITY, Calif. , March 1, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that Timothy

REDWOOD CITY, Calif. , Feb. 27, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced today the U.S.

REDWOOD CITY, Calif. , Feb. 23, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that it will release fourth

- Howie Rosen to Continue on Board of Directors - REDWOOD CITY, Calif. , Feb. 16, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe

REDWOOD CITY, Calif. , Feb. 13, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced an upcoming podium presentation

REDWOOD CITY, Calif. , Feb. 7, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that Timothy E.

· Expected FDA Acceptance of the NDA · Planned Submission of MAA in the EU · Potential Approval and Commercialization in the U.S. REDWOOD CITY, Calif. , Jan. 8, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and

REDWOOD CITY, Calif. , Jan. 8, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that the U.S.

REDWOOD CITY, Calif. , Dec. 13, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that it has submitted a New

- Peak revenue opportunity for ARX-04 estimated to be $1.1 billion - NDA for ARX-04 on track for submission by year-end REDWOOD CITY, Calif. , Dec. 6, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc . (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and

New speakers are: - Dr. Nathaniel Katz, CEO of Analgesic Solutions; Regulatory and Clinical Pain Expert - Dr. David Leiman, President of AIPM of Houston and Director of HD Research Corp.; Anesthesiologist and Principle Investigator REDWOOD CITY, Calif. , Nov.

REDWOOD CITY, Calif. , Nov. 17, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced an upcoming presentation at

- Expert panel to discuss market opportunity in emergency medicine for investigational agent ARX-04 (sufentanil sublingual tablet, 30 mcg) for the treatment of moderate-to-severe acute pain REDWOOD CITY, Calif. , Nov. 9, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc.

REDWOOD CITY, Calif. , Nov. 8, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that senior

REDWOOD CITY, Calif. , Nov. 1, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a business update and reported

REDWOOD CITY, Calif. , Oct. 31, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced an upcoming poster presentation

REDWOOD CITY, Calif. , Oct. 25, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain today announced that it will release Third Quarter financial

REDWOOD CITY, Calif. , Oct. 24, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced an upcoming poster presentation

REDWOOD CITY, Calif. , Sept. 28, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that the Company and

REDWOOD CITY, Calif. , Sept. 27, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced today the initiation of the

REDWOOD CITY, Calif. , Sept. 22, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that Dr.

REDWOOD CITY, Calif. , Sept. 22, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that Howie Rosen , chief

- Majority of Patients Had No Adverse Event; Similar Across All Subgroups - Pain Intensity Was Reduced by 27% at 1 Hour, 49% at 2 Hours, 57% at 12 Hours - Phase 3 Program Now Complete; AcelRx Intends to Submit ARX-04 NDA This Year REDWOOD CITY, Calif. , Sept.

Management to host conference call tomorrow at 9:00 a.m. ET (6:00 a.m. PT) Thursday, September 15th REDWOOD CITY, Calif. , Sept. 14, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) a specialty pharmaceutical company focused on the development and commercialization of innovative

REDWOOD CITY, Calif. , Aug. 31, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Timothy E.

REDWOOD CITY, Calif. , Aug. 29, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that the Company and its investigators will be presenting results from the Phase 3 SAP302 study of ARX-04 (sufentanil sublingual tablet, 30 mcg) in 76 patients who were treated for

- Topline SAP302 Results Presented at Military Health System Research Symposium - REDWOOD CITY, Calif. , Aug. 15, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the

REDWOOD CITY, Calif. , Aug 1, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that the Company and its investigators will be presenting top-line results from the initial cohort of 40 patients in single-arm, open-label Phase 3 SAP302 study, which assessed ARX-04

REDWOOD CITY, Calif. , July 28, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a corporate update and reported

REDWOOD CITY, Calif . , July 26, 2016 /PRNewswire/ --   AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain today announced that it will release Second Quarter

REDWOOD CITY, Calif. , July 6, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Chief Executive Officer, Howard

- Top-line results expected in Q3 2016 - REDWOOD CITY, Calif. , June 28, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain,

REDWOOD CITY, Calif. , June 27, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that the company has joined the

REDWOOD CITY, Calif. , June 2, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Senior Management will be presenting at

REDWOOD CITY, Calif. , May 26, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that the Company and its investigators will be presenting Phase 3 SAP301 study results at Euroanaesthesia 2016, which is taking place in London, UK on May 28-30, 2016 .

Results to be Presented at the 21st ISPOR Annual International Meeting REDWOOD CITY, Calif. , May 24, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today reported that the Company will be presenting an evaluation of the cost of delivering IV opioids in the emergency department

REDWOOD CITY, Calif. , May 6, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that the Company and its investigators will be presenting a subgroup analysis of the Phase 3 SAP301 study results by surgery type (abdominoplasty, hernioplasty and laparoscopic abdominal

REDWOOD CITY, Calif. , May 4, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Senior Management will be presenting at

REDWOOD CITY, Calif. , May 2, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a business update and reported

REDWOOD CITY, Calif. , April 28, 2016 /PRNewswire/ --   AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain today announced that it will release First Quarter

Conference call update at 4:30pm ET today REDWOOD CITY, Calif. , March 29, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute

- Zalviso Clinical Program Highlighted in Publication in Hospital Pharmacy - REDWOOD CITY, Calif. , March 25, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the

REDWOOD CITY, Calif. , March 14, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced the initiation of the

REDWOOD CITY, Calif. , March 7, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a business update and reported

REDWOOD CITY, Calif. , March 7, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced today that patient enrollment

REDWOOD CITY, Calif. , March 3, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that it will release fourth quarter and

REDWOOD CITY, Calif. , March 1, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Senior Management will be presenting at

REDWOOD CITY, Calif. , Feb. 25, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today reported encouraging interim

REDWOOD CITY, Calif. , Feb. 11, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that a podium presentation will be made at the 38th annual John A. Boswick , M.D. Burn and Wound Care Symposium, which is being held February 14-18, 2016 in Hawaii .

REDWOOD CITY, Calif. , Feb. 3, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Chief Financial Officer and Head of

Phase 3 Clinical Data Highlights Safety and Efficacy of Sublingual Sufentanil in Outpatient Abdominal Surgery Populations REDWOOD CITY, Calif. , Jan. 21, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that a presentation will be made at the annual European

- ARX-04 ER and Postoperative Study Results, NDA Submission - Initiation and Completion of Final Phase 3 trial in the U.S. for Zalviso, NDA Resubmission - Zalviso™ Commercial Launch in the European Union REDWOOD CITY, Calif. , Jan. 10, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.

REDWOOD CITY, Calif. , Jan. 8, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today reported that the Company has received comments

REDWOOD CITY, Calif. , Dec. 23, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the intended treatment of acute pain, reported that the Committee for Medicinal Products

- AcelRx Anticipates the Submission of the ARX-04 New Drug Application in the Second Half of 2016 - FDA Agrees to Include a Significant Number of Patients from the Zalviso Studies into the ARX‑04 Safety Database REDWOOD CITY, Calif. , Dec. 14, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc.

REDWOOD CITY, Calif. , Nov. 23, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that AcelRx Co-founder and Chief Medical

REDWOOD CITY, Calif. , Nov. 19, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, announced today that a moderated poster presentation will

REDWOOD CITY, Calif. , Nov. 10, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Chief Financial Officer Tim Morris

REDWOOD CITY, Calif. , Nov. 5, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Chief Financial Officer Tim Morris will

REDWOOD CITY, Calif. , Nov. 4, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, will be presenting at ObesityWeek 2015 an analysis from

REDWOOD CITY, Calif. , Oct. 29, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a business update and reported financial

REDWOOD CITY, Calif. , Oct 26, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that it will release Third Quarter financial

Presentation of Clinical Data from Recently Completed Phase 3 Study in Ambulatory Surgery Patients Highlights Efficacy and Tolerability of ARX-04 30 mcg REDWOOD CITY, Calif. , Oct. 23, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that a presentation will be made

Clinical Data from Phase 2 and Phase 3 Development Programs Highlight Efficacy and Tolerability of Sublingual Sufentanil in Out-patient Surgical Populations REDWOOD CITY, Calif. , Oct. 9, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that a presentation will be

REDWOOD CITY, Calif. , Oct. 8, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a regulatory update on Zalviso™ (sufentanil

REDWOOD CITY, Calif. , Oct. 6, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute and breakthrough pain, today announced the

REDWOOD CITY, Calif. , Oct. 1, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced the appointment of Gina Ford , RPh to the

REDWOOD CITY, Calif. , Sept. 24, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that the company will host an Analyst &

Approval triggers $15 million milestone payment to AcelRx from Grunenthal REDWOOD CITY, Calif. , Sept. 22, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) (AcelRx) announced today that the European Commission (EC) has approved Zalviso™ (15 micrograms sufentanil sublingual tablets)

REDWOOD CITY, Calif. , Sept. 21, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the monetization of the

Detailed SAP301 Results to be Presented at the American Society of Anesthesiologists Annual Meeting October 24-28, 2015 in San Diego, CA. REDWOOD CITY, Calif. , Sept. 9, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development

REDWOOD CITY, Calif. , Aug. 26, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will

REDWOOD CITY, Calif. , Aug. 3, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a business update and reported financial

REDWOOD CITY, Calif. , July 29, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release

REDWOOD CITY, Calif. , July 24, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive opinion for Zalviso™ (sufentanil sublingual

Results indicate Zalviso controlled moderate-to-severe acute pain following orthopedic surgery better than placebo, with similar side effect profile REDWOOD CITY, Calif. , July 2, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the

REDWOOD CITY, Calif. , May 22, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that interim chief executive

REDWOOD CITY, Calif. , May 14, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced it has entered into Contract No.

REDWOOD CITY, Calif. , May 4, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today provided a regulatory update on

REDWOOD CITY, Calif. , May 1, 2015   AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Timothy E.

REDWOOD CITY, Calif. , April 30, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release

Clinical Data from Two Different Development Programs Highlight Efficacy and Tolerability of Sublingual Sufentanil in Out-patient and In-patient Surgical Populations REDWOOD CITY, Calif. , April 14, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that a poster

AcelRx Announces Restructuring to Focus on Regulatory Approval of Zalviso and Clinical Development of ARX-04 REDWOOD CITY, Calif. , March 20, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and

SAP301 Trial to Study Sufentanil Sublingual Single-Dose Tablet for the Treatment of Moderate-to-Severe Acute Pain REDWOOD CITY, Calif. , March 16, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and

REDWOOD CITY, Calif. , March 9, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today reported financial results for the three

REDWOOD CITY, Calif. , March 9, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided an update on the timing and

REDWOOD CITY, Calif. , March 4, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release fourth

REDWOOD CITY, Calif. , Feb. 20, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Timothy E.

REDWOOD CITY, Calif. , Feb. 4, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Timothy E Morris,

REDWOOD CITY, Calif. , Dec. 2, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that it has received CE Mark

REDWOOD CITY, Calif. , Nov. 20, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management

Data from Sublingual Sufentanil Tablet System Development Program Highlights Efficacy across Various Demographic Populations REDWOOD CITY, Calif. , Nov. 13, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and

REDWOOD CITY, Calif. , Nov. 10, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results

REDWOOD CITY, Calif. , Nov. 10, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that it has been granted

REDWOOD CITY, Calif. , Nov. 7, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will

REDWOOD CITY, Calif. , Nov. 6, 2014 /PRNewswire/ --   AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release third

REDWOOD CITY, Calif. , Nov. 5, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the departure of Richard

Data from Sublingual Sufentanil Development Program Highlights Analgesic Response Compared to IV Morphine in Young vs Elderly Adult Patients REDWOOD CITY, Calif. , Oct. 27, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that multiple moderated poster presentations

Results indicate Zalviso controlled moderate-to-severe acute pain following abdominal surgery better than placebo, with similar side effect profile REDWOOD CITY, Calif. , Oct. 22, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that results from the  IAP310 study

Patent estate includes thirteen issued U.S. patents, thirty patents worldwide REDWOOD CITY, Calif. , Oct. 16, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the

Data from Sublingual Sufentanil Development Program Highlights Onset of Analgesia, Safety and Effect of Gender on Analgesic Response REDWOOD CITY, Calif. , Oct. 10, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that multiple moderated poster presentations will be

REDWOOD CITY, Calif. , Oct. 6, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that a new data analysis

REDWOOD CITY, Calif. , Sept. 26, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc.  (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today provided an update on the plans

REDWOOD CITY, Calif. , Sept. 10, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the publication of a

REDWOOD CITY, Calif. , Sept. 4, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the publication of the

REDWOOD CITY, Calif. , Aug. 27, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management

REDWOOD CITY, Calif. , Aug. 11, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results

REDWOOD CITY, Calif. , Aug. 8, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will

REDWOOD CITY, Calif. , Aug. 7, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release second

REDWOOD CITY, Calif. , July 25, 2014 /PRNewswire/ --   AcelRx Pharmaceuticals, Inc.  (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the U.S.

REDWOOD CITY, Calif. , July 24, 2014 /PRNewswire/ --   AcelRx Pharmaceuticals, Inc.  (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today confirmed the PDUFA date for

- MAA submission triggers $5 million milestone payment to AcelRx REDWOOD CITY, Calif. and AACHEN, Germany , July 7, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) and Grunenthal Group announced today that Grunenthal has submitted a Marketing Authorization Application (MAA) to the

REDWOOD CITY, Calif. , June 19, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management

Additionally, Results of Independent Survey Show IV PCA a Burden for Postoperative Care Nurses Both Cost Analysis and Survey Findings Underscore Need for Cost-Effective, Patient and Nurse Friendly In-Hospital Pain Management Innovations REDWOOD CITY, Calif.

REDWOOD CITY, Calif. , June 2, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that David Chung has

REDWOOD CITY, Calif. , May 29, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will

REDWOOD CITY, Calif. , May 19, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,

REDWOOD CITY, Calif. , May 8, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the

REDWOOD CITY, Calif. , May 2, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release first

REDWOOD CITY, Calif. , May 1, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that multiple Zalviso and

REDWOOD CITY, Calif. , April 4, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,

REDWOOD CITY, Calif. , March 25, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the appointment of

REDWOOD CITY, Calif. , March 7, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,

REDWOOD CITY, Calif. , March 3, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the

REDWOOD CITY, Calif. , Feb. 24, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release fourth

REDWOOD CITY, Calif. , Feb. 5, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,

REDWOOD CITY, Calif., Dec. 19, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it has entered

- FDA establishes the PDUFA action date of July 27, 2014 for Zalviso - - Conference Call Scheduled Monday, December 16th 2013 for 8:30 a.m. Eastern Time - REDWOOD CITY, Calif. and AACHEN, Germany , Dec. 16, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.

- 30 mcg sufentanil NanoTab treatment group experienced rapid onset of action with statistically significant pain relief and reduced pain intensity at 30 minutes - REDWOOD CITY, Calif. , Dec. 13, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company

REDWOOD CITY, Calif. , Dec. 11, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard F.

REDWOOD CITY, Calif. , Dec. 2, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the Zalviso ™ New Drug

REDWOOD CITY, Calif. , Nov. 26, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,

REDWOOD CITY, Calif. , Nov. 5, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX),  a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the

REDWOOD CITY, Calif. , Oct. 22, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release third

First medical meeting data presentations from Phase 3 clinical trial conducted in orthopedic surgery patients REDWOOD CITY, Calif. , Oct. 15, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of

Patent estate includes nine issued U.S. patents, nineteen patents worldwide REDWOOD CITY, Calif. , Oct. 8, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment

Zalviso NDA submitted for the management of moderate-to-severe acute pain in adult patients in the hospital setting REDWOOD CITY, Calif. , Sept. 30, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization

REDWOOD CITY, Calif. , Sept. 4, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that David H.

REDWOOD CITY, Calif. , Aug. 30, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,

REDWOOD CITY, Calif. , Aug. 12, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial

REDWOOD CITY, Calif. , Aug. 5, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,

REDWOOD CITY, Calif. , Aug. 2, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release second

REDWOOD CITY, Calif. , July 23, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), today announced the closing of the public offering of 4,370,000 shares of common stock, including 570,000 shares of common stock which were issued pursuant to the exercise of the underwriters' option

REDWOOD CITY, Calif. , July 18, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) today announced the pricing of its previously announced underwritten public offering of 3.8 million shares of its common stock, offered at a price of $11.65 per share to the public.

REDWOOD CITY, Calif. , July 17, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an

REDWOOD CITY, Calif. , July 2, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, has joined the broad-market Russell 3000 ®

REDWOOD CITY, Calif. , July 1, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that on July 9, 2013 the

REDWOOD CITY, Calif. , June 21, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, will host an Investor Day on Thursday, June

REDWOOD CITY, Calif. , May 29, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,

- Following major orthopedic surgery, Sufentanil NanoTab-treated patients experienced significantly greater reduction in pain as measured by SPID-48 vs. placebo (p<0.001) - - Results confirm all previously reported Phase 3 trial outcomes, supporting submission of an NDA anticipated for third

REDWOOD CITY, Calif. , May 16, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,

REDWOOD CITY, Calif. , May 8, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results

REDWOOD CITY, Calif. , May 3, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release first

- Additional Phase 3 analysis show significantly faster reduction in pain and fewer patients with oxygen desaturation events for Sufentanil NanoTab PCA System than IV PCA with morphine - - Sufentanil NanoTab PCA System remains on track for a Q3 2013 NDA submission - REDWOOD CITY, Calif.

- Patients in the 30 mcg sufentanil NanoTab treatment group experienced significantly greater reduction in pain as measured by SPID-12 vs. placebo - - ARX-04 is a rapid-onset, non-invasive investigational pain medication being evaluated for the short-term treatment of acute moderate-to-severe pain

REDWOOD CITY, Calif. , March 12, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial

REDWOOD CITY, Calif. , March 7, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release

- Patients experienced significantly greater reduction in pain as measured by SPID-48 vs. placebo (p=0.001) - - Adverse events in sufentanil-treated patients similar to placebo - - AcelRx to conduct conference call and webcast tomorrow, March 5, at 8:30 a.m. EST (5:30 a.m.

REDWOOD CITY, Calif. , Feb. 27, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that AcelRx will present a

Continued progress towards NDA submission for Sufentanil NanoTab PCA System in Q3 2013 REDWOOD CITY, Calif. , Feb. 19, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for

REDWOOD CITY, Calif., Feb. 12, 2013 /PRNewswire via COMTEX/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the appointment of

REDWOOD CITY, Calif. , Dec. 14, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), announced today that the underwriters of its public offering have exercised, in full, their option to purchase an additional 1,875,000 shares of common stock at a public offering price of $3.31 per

- First medical meeting presentation of top-line Phase 3 data demonstrating NanoTab System met both non-inferiority and superiority comparisons to IV PCA with morphine in open-label study - REDWOOD CITY, Calif. , Dec. 14, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc.

REDWOOD CITY, Calif. , Dec. 6, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), today announced the pricing of its previously announced underwritten public offering of 12,500,000 shares of its common stock, offered at a price of $3.31 per share to the public.  The gross proceeds to

REDWOOD CITY, Calif. , Dec. 5, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), today announced a proposed underwritten public offering of 10,000,000 shares of its common stock pursuant to a registration statement filed with the Securities and Exchange Commission (" SEC ").  

REDWOOD CITY, Calif. , Nov. 20, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,

-In this open-label study, the Sufentanil NanoTab PCA System also demonstrated statistical superiority to IV PCA morphine for primary endpoint of Patient Global Assessment of method of pain control - Nurses and patients rated Sufentanil NanoTab PCA System higher for Overall Satisfaction and Ease of

REDWOOD CITY, Calif. , Nov. 14, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced today it had met the primary

REDWOOD CITY, Calif. , Nov. 6, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the

- Phase 2 placebo-controlled, dose-finding study funded by a grant from the Department of Defense - REDWOOD CITY, Calif. , Nov. 5, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative

REDWOOD CITY, Calif. , Nov. 1, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release third

Centralized review process used for products that provide a significant therapeutic, scientific or technical innovation to patient health REDWOOD CITY, Calif. , Oct. 3, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development

REDWOOD CITY, Calif. , Sept. 18, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Mike A.

REDWOOD CITY, Calif. , Sept. 10, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,

Two more U.S. patents expand intellectual property protection for AcelRx's pipeline of sufentanil NanoTab® pain products REDWOOD CITY, Calif. , Aug. 29, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and

First orthopedic surgery patient dosed in randomized, double-blind, placebo-controlled trial REDWOOD CITY, Calif. , Aug. 23, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies

REDWOOD CITY, Calif. , Aug. 23, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,

REDWOOD CITY, Calif. , Aug. 9, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial

REDWOOD CITY, Calif. , Aug. 8, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. ("AcelRx") (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced today that Richard

REDWOOD CITY, Calif. , Aug. 7, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release second

Two new U.S. patents expand intellectual property protection for AcelRx pipeline of sufentanil NanoTab® pain products REDWOOD CITY, Calif. , Aug. 1, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization

Company invites individual and institutional investors to log-on to view July 12th presentation NEW YORK , July 20, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the

Company invites Main Street and Wall Street investors to attend interactive real-time virtual conference NEW YORK , July 10, 2012  /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies

REDWOOD CITY, Calif. , June 28, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,

- First U.S. patent provides intellectual property protection for AcelRx pipeline of NanoTab® pain products through 2030- REDWOOD CITY, Calif. , June 20, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and

REDWOOD CITY, Calif. , June 4, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. ("AcelRx") (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced today that Richard King

REDWOOD CITY, Calif. , June 4, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced today that it completed its

REDWOOD CITY, Calif. , May 30, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced today that it has obtained

REDWOOD CITY, Calif. , May 8, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results

REDWOOD CITY, Calif., April 17, 2012 /PRNewswire via COMTEX/ --AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the appointment of

First Subject Dosed in Open-Label, Active-Comparator Trial REDWOOD CITY, Calif., April 12, 2012 /PRNewswire via COMTEX/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the

First US allowances could provide for intellectual property protection for AcelRx pipeline of NanoTab® pain products until at least 2029. REDWOOD CITY, Calif. , April 11, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and

REDWOOD CITY, Calif. , March 20, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial

First Subject Dosed in Abdominal Surgery Trial with Top-Line Data Expected in H2 2012 REDWOOD CITY, Calif. , March 6, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative

REDWOOD CITY, Calif. , Feb. 21, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,

   REDWOOD CITY, Calif. , Jan. 31, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, reported that the two

REDWOOD CITY Calif. , Nov. 23, 2011 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,

REDWOOD CITY, Calif., Nov. 8, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, reported financial

REDWOOD CITY, Calif., Sept. 28, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc., (NASDAQ: ACRX) ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced that Mark

REDWOOD CITY, Calif., Sept. 15, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard

REDWOOD CITY, Calif., Sept. 9, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King

REDWOOD CITY, Calif., Aug. 25, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King

Remains On Track to Initiate First ARX-01 Phase 3 Clinical Trial Later This Year REDWOOD CITY, Calif., Aug. 11, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative

REDWOOD CITY, Calif., Aug. 10, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King

REDWOOD CITY, Calif., June 30, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) (AcelRx) today announced that it has obtained a $20 million secured loan agreement with Hercules Technology Growth Capital (Hercules). Upon the execution of this agreement with Hercules,

REDWOOD CITY, Calif., May 31, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)(AcelRx), today announced that the US Army Medical Research and Material Command (USAMRMC) has awarded AcelRx a $5.6 million grant to support the development of a new product candidate, ARX-04,

REDWOOD CITY, Calif., May 18, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. announced today that the results from its Phase 2 clinical studies related to two product candidates, ARX-01 Sufentanil NanoTab(R) PCA System, which is designed to solve the problems associated with

Initiation of Phase 3 Trial for Lead Product Candidate ARX-01 On Track for Second Half of 2011 REDWOOD CITY, Calif., May 12, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization

REDWOOD CITY, Calif., May 10, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc., (NASDAQ: ACRX) ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced that the

REDWOOD CITY, Calif., May 6, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,

Plans to Initiate the Phase 3 Program for Lead Product Candidate ARX-01 in Second Half of 2011; IPO Completed REDWOOD CITY, Calif., March 24, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and

REDWOOD CITY, Calif., March 7, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King

REDWOOD CITY, Calif. , Feb. 11, 2011 - AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the pricing of its initial public

REDWOOD CITY, Calif., Nov. 12, 2010 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock.

REDWOOD CITY, Calif., October 4, 2010 – AcelRx Pharmaceuticals, Inc. announced today that James H. Welch has joined the company as Chief Financial Officer. “We are very fortunate to continue to attract seasoned leaders in the pharmaceutical industry” stated Richard King, AcelRx President and CEO.

REDWOOD CITY, Calif., October 1, 2010 -- AcelRx Pharmaceuticals, Inc. today announced that it has completed an End-of-Phase 2 meeting with the US Food and Drug Administration (FDA) for ARX-02, a proprietary Sufentanil NanoTabTM Breakthrough Pain Management System for the treatment of cancer

Study achieved primary and secondary endpoints and showed rapid onset of pain relief in cancer patients experiencing breakthrough pain REDWOOD CITY, Calif., May 25, 2010 – AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical study evaluating the safety and efficacy

REDWOOD CITY, Calif., April 20, 2010 -- AcelRx Pharmaceuticals, Inc. announced today that results of its Phase 2 studies evaluating the safety and efficacy of the ARX-01 sublingual Sufentanil NanoTabTM PCA System will be featured in three poster presentations at the upcoming 35th Annual Regional

REDWOOD CITY, Calif., April 6, 2010 -- AcelRx Pharmaceuticals, Inc. today announced the appointment of Richard King as president and chief executive officer. Mr. King will lead AcelRx’s efforts to advance the Company’s portfolio of products using its novel NanoTab™ platform technology.

REDWOOD CITY, Calif., November 13, 2009 -- AcelRx Pharmaceuticals, Inc. today announced that Thomas Schreck, President & Chief Executive Officer, and Pamela Palmer, MD, PhD, Chief Medical Officer, will be presenting at the Lazard Capital Markets 6th Annual Healthcare Conference to be held November

REDWOOD CITY, Calif., October 22, 2009 -- AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical trial of ARX-03, a proprietary sublingual dosage form combining an opioid, sufentanil, with a benzodiazepine, triazolam. ARX-03 is designed to address the current unmet

Two abstracts selected for oral presentations Tuesday, October 20 in New Orleans REDWOOD CITY, Calif., October 15, 2009 -- AcelRx Pharmaceuticals, Inc. announced today that results of its Phase 1 studies evaluating the pharmacokinetics of its oral transmucosal NanoTab™ formulation of sufentanil

REDWOOD CITY, Calif., October 14, 2009 -- AcelRx Pharmaceuticals, Inc. announced today that Nigel Ray has joined the company as Vice President of Business Development. In this new position, Mr. Ray will lead AcelRx’s partnering efforts for its mid- and late-stage clinical products including the

Efficacy consistent with positive results from earlier placebo-controlled studies REDWOOD CITY, Calif., July 22, 2009 -- AcelRx Pharmaceuticals, Inc. today announced positive results from its first Phase 2 clinical study evaluating the functionality of the handheld device component of its ARX-01

Study in major abdominal surgery patients achieved primary and secondary endpoints REDWOOD CITY, Calif., June 29, 2009 -- AcelRx Pharmaceuticals, Inc. today announced positive results from the second Phase 2 clinical study evaluating the safety and efficacy of its ARX-01 Sufentanil NanoTabs™ for

REDWOOD CITY, Calif., May 5, 2009 -- AcelRx Pharmaceuticals, Inc. today announced that it has initiated a Phase 2 clinical trial of its ARX-01 Sufentanil NanoTab™ PCA System, a proprietary drug/device combination product candidate being developed for management of acute post-operative pain in the

REDWOOD CITY, Calif., April 22, 2009 -- AcelRx Pharmaceuticals, Inc. today announced that it has initiated a Phase 2 clinical trial of ARX-02, a proprietary sublingual sufentanil NanoTab™ product candidate for cancer breakthrough pain control. The primary objective of this multicenter, randomized,

REDWOOD CITY, Calif., March 6, 2009 -- AcelRx Pharmaceuticals, Inc. announced today it has hired Mark Evashenk as Vice President, Clinical Operations. In this new position, Mr. Evashenk will assist in defining developmental strategy, guiding clinical protocol design and study conduct, and managing

REDWOOD CITY, Calif., January 12, 2009 ‐‐ AcelRx Pharmaceuticals, Inc., an emerging specialty pharmaceutical company focused on the treatment of intermittent and acute medical conditions with an initial emphasis on pain management, today announced positive results from a Phase 1 clinical study

REDWOOD CITY, Calif., December 23, 2008 -- AcelRx Pharmaceuticals, Inc., an emerging specialty pharmaceutical company focused on the treatment of intermittent and acute conditions, with an initial emphasis on pain management, announced that it will present at JP Morgan’s 27th Annual Healthcare

REDWOOD CITY, Calif., December 9, 2008 ‐‐ AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical study evaluating the safety and efficacy of its lead product candidate, ARX‐01, for the treatment of moderate‐to‐severe inpatient acute pain following knee replacement